Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Total Liabilities (2019 - 2025)

aTYR PHARMA's Total Liabilities history spans 7 years, with the latest figure at $25.5 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 4.8% year-over-year to $25.5 million; the TTM value through Dec 2025 reached $25.5 million, down 4.8%, while the annual FY2025 figure was $25.5 million, 4.8% down from the prior year.
  • Total Liabilities reached $25.5 million in Q4 2025 per ATYR's latest filing, down from $26.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $30.2 million in Q4 2023 to a low of $5.6 million in Q1 2021.
  • Average Total Liabilities over 5 years is $20.3 million, with a median of $25.0 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: crashed 55.16% in 2021, then skyrocketed 323.93% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $6.4 million in 2021, then skyrocketed by 282.19% to $24.5 million in 2022, then rose by 23.19% to $30.2 million in 2023, then fell by 11.17% to $26.8 million in 2024, then decreased by 4.8% to $25.5 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Total Liabilities are $25.5 million (Q4 2025), $26.4 million (Q3 2025), and $26.9 million (Q2 2025).